~~<i id='C0488C2009'><strike id='C0488C2009'><tt id='C0488C2009'><pre id='C0488C2009'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

author：knowledge 2025-09-29 22:51:07 - browse：7245

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Medicare Advantage overpayments discussion gets experts fired up

hotspot

entertainment

knowledge

focus

hotspot

hotspot

hotspot

2:45DemocraticpresidentialcandidateRobertF.KennedyJr.deliversaforeignpolicyspeechatSt.AnselmCollegei

WSS

Care demand spikes challenge UnitedHealth’s provider arm

Involuntary treatment for addiction doesn't work

Allen Institute goes after foundational questions, CEO Costa says

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Congress likely to miss an opportunity to fix drug shortages issue

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Wikipedia

Wikipedia

hotspot

Drug repurposing or repositioning? The language matters

Life science postdocs should get big pay hike, NIH panel says

Continuity nursing helped my family in our darkest PICU moments

Ascension's ugly legal battle over care for poor patients in Texas

Trump demands the U.S. pay no more for drugs than other countries … again

Blood tests recalled over risk of missed heart attack diagnosis

Psychedelics group wrestles with new pharma identity

Does aspartame cause cancer? What new WHO guidance says

BioMarin wins approval for gene therapy to treat hemophilia A

Gene therapy denied for Afghan refugee whose father aided U.S.

entertainment

Federal judge rules Oregon’s tough new gun law is constitutional

Boston Scientific acquires urology company Axonics for $3.7 billion

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Profiling embryos to choose those with higher IQs is almost a reality

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

knowledge

focus

hotspot

hotspot